山东步长制药股份有限公司关于拟放弃优先受让控股子公司股权的进展公告

Group 1: Transaction Overview - Shandong Buchang Pharmaceutical Co., Ltd. plans to waive its preferential right to acquire a 1.00% equity stake in its subsidiary, Shandong Buchang Zhongxin Kang Pharmaceutical Technology Co., Ltd., held by shareholder Wei Lihua, with a transfer price of 25,000 yuan [2] - After the transfer, the company's ownership in Buchang Zhongxin Kang remains at 90% [2] - A supplementary agreement regarding the cooperation agreement has been signed, confirming that Wei Lihua will no longer hold any rights or obligations related to the target equity [3] Group 2: Drug Registration Announcement - The subsidiary, Jilin Tiancheng Pharmaceutical Co., Ltd., has received a drug registration certificate for Lacosamide Injection from the National Medical Products Administration [6] - Lacosamide Injection is indicated for the adjunctive treatment of partial-onset seizures in patients aged 4 years and older [6] - Projected annual sales for Lacosamide Injection are expected to grow from 35.79 million yuan in 2022 to 306.87 million yuan in 2024 [7] Group 3: R&D Investment - The company has invested approximately 12.52 million yuan in research and development for the Lacosamide Injection project [8]